PuSH - Publikationsserver des Helmholtz Zentrums München

33 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
Alle Publikationen dieser Seite in den Korb legen
Salminen, A.V. et al.: Reply to: A note on rotigotine for restless legs syndrome after renal transplantation. Mov. Disord. 34, 152-153 (2019)
Salminen, A.V. et al.: Reply to: Safety of dopamine agonists for treating restless legs syndrome. Mov. Disord. 34, 150-151 (2019)
Bartl, M.* ; Winkelmann, J. ; Högl, B.* ; Paulus, W.* & Trenkwalder, C.*: Frequent neurological diseases associated with the restless legs syndrome. Nervenarzt 89, 1156-1164 (2018)
Ouled Amar Bencheikh, B.* et al.: LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder. Parkinsonism Relat. Disord. 52, 98-101 (2018)
Trenkwalder, C.* et al.: Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurol. 17, 994-1005 (2018)
Winkelmann, J. et al.: Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§. Mov. Disord. 33, 1077-1091 (2018)
Müller-Rebstein, S.* et al.: Pharmakotherapie des Morbus Parkinson. Aspekte der Arzneimitteltherapiesicherheit. Nervenarzt, 1-7 (2017)
Schormair, B. et al.: Diagnostic exome sequencing in early-onset Parkinson's disease confirms VPS13C as a rare cause of autosomal-recessive Parkinson's disease. Clin. Genet. 93, 603-612 (2017)
Schormair, B. et al.: Identification of novel risk loci for restless legs syndrome: A meta-analysis of genome-wide association studies in individuals of European ancestry: A meta-analysis. Lancet Neurol. 16, 898–907 (2017)
Trenkwalder, C.* et al.: Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Mov. Disord. 32, 1478-1482 (2017)
Trenkwalder, C.* ; Allen, R.P.* ; Högl, B.* ; Paulus, W.* & Winkelmann, J.: Restless legs syndrome associated with major diseases: A systematic review and new concept. Neurology 86, 1336-1343 (2016)
Schulte, E.C. et al.: Rare variants in β-Amyloid Precursor Protein (APP) and Parkinson's disease. Eur. J. Hum. Genet. 23, 1328-1333 (2015)
Schulte, E.C. et al.: Rare variants in LRRK1 and Parkinson's disease. Neurogenetics 15, 49-57 (2014)
Schulte, E.C. et al.: Blood cis-eQTL analysis fails to identify novel association signals among sub-threshold candidates from genome-wide association studies in restless legs syndrome. PLoS ONE 9:e98092 (2014)
Schulte, E.C. et al.: Targeted resequencing and systematic in vivo functional testing identifies rare variants in MEIS1 as significant contributors to restless legs syndrome. Am. J. Hum. Genet. 95, 85-95 (2014)
Hopfner, F. et al.: The role of SCARB2 as susceptibility factor in Parkinson's disease. Mov. Disord. 28, 538-540 (2013)
Oexle, K.* et al.: Dilution of candidates: The case of iron-related genes in restless legs syndrome. Eur. J. Hum. Genet. 21, 410-414 (2013)
Schulte, E.C. et al.: Rare variants in PLXNA4 and Parkinson's disease. PLoS ONE 8:e79145 (2013)
Trenkwalder, C.* et al.: Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: A double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 12, 1141-1150 (2013)
Zech, M. et al.: Niemann-pick C disease gene mutations and age-related neurodegenerative disorders. PLoS ONE 8:e82879 (2013)